A polymer–drug conjugate for doxorubicin: Synthesis and biological evaluation of pluronic F127-doxorubicin amide conjugates
Qihe Gao
School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210000, China
Search for more papers by this authorXuelian Han
School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210000, China
Search for more papers by this authorJin Zhu
Huadong Medical Institute of Biotechniques, Nanjing 210002, China
Search for more papers by this authorRenjie Chen
Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China
Search for more papers by this authorCorresponding Author
Baiwang Sun
School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210000, China
School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210000, China===Search for more papers by this authorQihe Gao
School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210000, China
Search for more papers by this authorXuelian Han
School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210000, China
Search for more papers by this authorJin Zhu
Huadong Medical Institute of Biotechniques, Nanjing 210002, China
Search for more papers by this authorRenjie Chen
Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China
Search for more papers by this authorCorresponding Author
Baiwang Sun
School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210000, China
School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210000, China===Search for more papers by this authorAbstract
Higher molecular weight of the polymer carrier is the basis for enhanced accumulation of the pro-drug in a solid tumor tissue due to a tumor-related phenomenon described as the enhanced permeability and retention (EPR) effect. The anticancer drug doxorubicin was covalently bound to F127 through amide group susceptible to lysosomal hydrolysis. The in vitro and in vivo properties of F127-DOX amide conjugates were studied. F127-DOX amide conjugates (Mw: 13,400) were stable in neutral circumstance and showed the potency and mechanism of action of the released drug. In the in vivo experiment, results showed that F127-DOX amide conjugates prolonged blood circulation and lowered in vivo toxicity than corresponding DOX, which illustrated the importance of molecular weight. The results demonstrated that F127-DOX amide conjugates may be very promising and clinically suitable candidates for anticancer therapy. © 2011 Wiley Periodicals, Inc. J Appl Polym Sci, 2011
References
- 1 Blum, R. H.; Carter, S. H. Ann Intern Med 1974, 80, 249.
- 2 Al-Shabanah, O. A.; El-Kashef, H. A.; Badary, O. A.; Al-Bekairi, A. M.; Elmazar, M. M. A. Pharmacol Res 2000, 41, 31.
- 3 Krishna, R.; Mayer, L. D. Eur J Pharm Sci 2000, 11, 265.
- 4 Matsumura, Y.; Maeda, H. Cancer Res 1986, 6, 6387.
- 5 Maeda, H. Adv Enzyme Regul 2001, 41, 189.
- 6 Maeda, H.; Matsumura, Y. Ther Drug Carr Syst 1989, 6, 193.
- 7 Segal, E.; Ronit, S. F. Adv Drug Deliver Rev 2009, 61, 1159.
- 8 Cao, N.; Feng, S. S. Biomaterials 2008, 29, 3856.
- 9 Duncan, R.; Kopeček, J. Adv Polym Sci 1984, 57, 51.
- 10 Garnett, M. C. Adv Drug Deliv Rev 2001, 53, 171.
- 11 Etrych, T.; Chytil, P.; Mrkvan, T.; Šírová, M.; Říhová, B.; Ulbrich, K. J Controlled Release 2008, 132, 184.
- 12 Guo, D. D.; Xu, C. X.; Quan, J. S.; Song, C. K.; Jin, H.; Kim, D. D.; Choi, Y. J.; Cho, M. H.; Cho, C. S. Biomaterials 2009, 30, 4777.
- 13 Schmolka, I. R. Ann NY Acad Sci 1994, 92, 720.
- 14 Batrakova, E. V.; Kabanov, A. V. J Controlled Release 2008, 130, 98.
- 15 Batrakova, E. V.; Li, S.; Alakhov, V. Y.; Elmquist, W. F.; Miller, D. W.; Kabanov, A. V. Pharm Res 2003, 20, 1581.
- 16 Batrakova, E. V.; Li, S.; Elmquist, W. F.; Miller, D. W.; Alakhov, V. Y.; Kabanov, A. V. Br J Cancer 2001, 85, 1987.
- 17 Kabanov, A. V.; Batrakova, E. V.; Alakhov, V. Y. J Controlled Release 2003, 91, 75.
- 18 Venne, A.; Li, S.; Mandeville, R.; Alakhov, A. V. Cancer Res 1996, 56, 3626.
- 19 Minko, T.; Batrakova, E. V.; Li, S.; Li, Y.; Pakunlu, R. I.; Alakhov, V. Y.; Kabanov, A. V. J Controlled Release 2005, 105, 269.
- 20 Batrakova, E. V.; Li, S.; Brynskikh, A. M.; Sharma, A. K.; Li, Y.; Boska, M.; Gong, N.; Mosley, R. L.; Alakhov, V. Yu.; Gendelman, H. E.; Kabanov, A. V. J Controlled Release 2010, 143, 290.
- 21 Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. J Controlled Release 2008, 126, 187.
- 22 Hruby', M.; Konˇa'k, C.; Ulbrich, K. J Controlled Release 2005, 103, 137.
- 23 Treetharnmathurot, B.; Ovartlarnporn, C.; Wungsintaweekul, J.; Duncand, R.; Wiwattanapatapee, R. Int J Pharm 2008, 357, 252.
- 24 Ur-Rehman, T.; Tavelin1, S.; Gröbner, G. Int J Pharma 2011, 409, 19.
- 25 Sauer, I.; Dunay, I. R.; Weisgraber, K.; Bienert, M.; Dathe, M. Biochemistry 2005, 44, 2021.
- 26 Managit, C.; Kawakami, S.; Yamashita, F.; Hashida, M. Int J Pharm 2005, 301, 255.
- 27 Jedema, I.; Barge, R. M. Y.; van der Velden, V. H. J.; Nijmeijer, B. A.; van Dongen, J. J. M.; Willemze, R.; Falkenburg, J. H. F. Leukemia 2004, 18, 316.
- 28 Doronina, S. O.; Toki, B. E.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; Chace, D. F. Nat Biothechnol 2003, 21, 778.
- 29 Sanderson, R. J.; Hering, M. A.; James, S. F.; Sun, M. M. C.; Doronina, S. O.; Siadak, A. W.; Senter, P. D.; Wahl, A. F. Clin Cancer Res 2005, 11, 843.
- 30 Yoo, H. S.; Park, T. G. J Controlled Release 2004, 100, 247.
- 31 Etrych, T.; Jel'ınkova', M.; Ulbrich, K. J Controlled Release 2001, 73, 89.
- 32 Francisco, J. A.; Cerveny, C. G.; Meyer, D. L.; Mixan, B. J.; Klussman, K.; Chace, D. F.; Rejniak, S. X.; Gordon, K. A.; DeBlanc, R.; Toki, B. E.; Law, C. L.; Doronina, S. O.; Siegall, C. B.; Senter, P. D.; Wahl, A. F. Blood 2003, 102, 1458.
- 33 Larsen, A. K.; Escargueil, A. E.; Skladanowski, A. Pharmacol Ther 2000, 85, 217.
- 34 Schmid, S. L.; Carter, L. Cell Biol 1990, 111, 2307.
- 35 Senter, P. D. Curr Opin Chem Biol 2009, 13, 235.
Citing Literature
